SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back




Title
: Clinical Updates for Nurse Practitioners and Physician Assistants: 2018 Seattle, WA
Activity/Course #:
: 09.22.18CU

Cost:
: Free
Release/Start Date:
: Sep 22 2018
Expiration Date:
: Sep 22 2018
Topics:
: Primary Care Medicine
Target Audience:
: Nurse Practitioners, Physician Assistants, and Physicians
Format:
: Live NP PA Conference
Estimated Time To Complete CME Activity:
: 7.0 hours
Credit(s):
: 7.0 AMA PRA Category I Credit(s)
7.0 AANP Contact hour(s) which includes 4.25 pharmacology hour(s)
Hardware/Software Requirements:


Saturday, September 22, 2018

Seattle Airport Marriott
3201 S 176th St
Seattle, WA 98188
(206) 241-2000

Registration Fee

There is no registration fee for this activity.

Special Accommodations

NACE fully complies with the legal requirements of the Americans with Disabilities Act. Any activity registrant who feels s/he may need accommodations based on the impact of a disability should contact NACE to discuss your specific need.

Event Parking

A discounted self parking rate of $10 is available at the hotel.

Program Summary

Nurse practitioners and physician assistants as primary care providers face complex challenges every day in their busy practices. With rapid changes in medicine, staying informed about new developments can be equally challenging. Our goal in this CME activity is to help you hone your skills in the diagnosis and management of patients with varied conditions you are likely encountering in your practice.

We have recruited a faculty of well-known thought leaders and experienced teachers who, as clinicians themselves, understand the challenges you face every day as a primary care provider. Our faculty will be at your disposal to provide evidence-based science, current treatment guidelines, discuss challenging cases, and provide answers for you that can ultimately lead to better health care for your patients. The presentations will include several interactive cases and discussion sessions to keep you actively learning.

Please join us and become an active participant in this one-day learning community of your peers.

Learning Objectives

At the conclusion of this program, participants should be able to:

1. Discuss the benefits of a pathophysiologic vs algorithmic approach to type 2 diabetes mellitus (T2DM) management; Utilize effective strategies to overcome barriers to therapeutic intensification and clinical inertia in T2DM management; Realize the limits of basal insulin therapy in clinical practice and when there is a greater need to address post-prandial hyperglycemia; Identify patients who are most likely to benefit from combined basal insulin-GLP-1RA therapy as an effective means of combining endogenous/exogenous insulin therapy.

2. Discuss clinician and patient barriers to initiation and intensification of insulin therapy; Recognize the prevalence and clinical impact of hypoglycemia in special populations at risk; Discuss the pharmacology and clinical differences between existing and new long-acting and concentrated insulins; Discuss how to incorporate new basal and concentrated insulins into clinical practice while minimizing the risk of adverse events.

3. Describe “case-finding” strategies to identify patients with unrecognized, but clinically significant COPD; Tailor COPD pharmacotherapy according to current recommended therapeutic strategies which incorporate unique patient needs and characteristics; Discuss strategies to facilitate the appropriate use of inhaled therapies for COPD, including the importance of proper inhaler technique; Recognize appropriate strategies to prevent and manage COPD exacerbations and to provide transitions of care post hospitalization.

4. Review the risk factors and classification of pulmonary hypertension (PH); Discuss the appropriate diagnostic strategy for pulmonary arterial hypertension (PAH), including the roles of echocardiography, ventilation/perfusion (V/Q) scanning, and right heart catheterization (RHC); Review current and emerging treatments for patients with PAH; Describe how to monitor patients with PAH for disease progression.

5. Recognize the role of laboratory testing and imaging in the evaluation and management of HF; Reliably assess symptom burden in patients with HF; Implement ACC/AHA/HFSA guideline directed medical therapy in the management of chronic heart failure, Recognize strategies to reduce hospitalization and readmission for HF.

6. Describe the findings from recent trials of PCSK9i hypercholesterolemia treatments on cardiovascular outcomes; Discuss current guidelines and recommendations on the management of hyperlipidemia in high risk patients; Incorporate current data into secondary prevention treatment strategies for patients with the highest cardiovascular risk; Recognize barriers to access for PCSK9 monoclonal antibody therapy and discuss novel strategies to overcome them.

Agenda*

 7:30-8:00   
Continental Breakfast and Registration 
 8:00-8:10   Welcome Remarks
Jack Kravitz, MD
 8:10-9:20   Combination Basal Insulin and GLP-1 RA Therapy: A Physiologic Approach to Diabetes Care
Jeff Unger, MD, ABFP, FACE and Robert S. Busch, MD, FACE
 9:20-10:30   Advances in Insulin Therapy: Another Step Closer to a More Physiological Strategy
Jeff Unger, MD, ABFP, FACE and Robert S. Busch, MD, FACE
 10:30-10:50   Break
 10:50-12:00   Optimizing COPD Management in Primary Care
Arunabh Talwar, MD, FCCP
12:00-1:00
  Lunch
 1:00-2:10   Recognizing and Managing Pulmonary Arterial Hypertension in Primary Care
Arunabh Talwar, MD, FCCP
 2:10-3:20   Heart Failure: Optimizing Medical Therapy and Patient Communication
Robert L. Gillespie, MD, FACC, FASE, FASNC
 3:20-3:30 Break
 3:30-4:40 Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care
Robert L. Gillespie, MD, FACC, FASE, FASNC
 4:40-4:45   Closing Remarks
Jack Kravitz, MD

* Agenda subject to change

 

Faculty

Robert S. Busch, MD, FACE
Director of Clinical Research
Albany Medical Faculty: Community Endocrine Group
Albany, NY

Robert L. Gillespie, MD, FACC, FASE, FASNC
Immediate Past Chairman of the Board
Association of Black Cardiologists, Inc.
Director of Nuclear Imaging
Sharp Rees-Stealy Medical Group
San Diego, CA

Arunabh Talwar, MD, FCCP
Director, Pulmonary Hypertension and Advanced Lung
Disease Program
North Shore University Hospital, Manhasset, New York
Professor of Medicine
Hofstra North Shore-LIJ School of Medicine
Hofstra University
Hempstead, NY

Jeff Unger, MD, ABFP, FACE
Assistant Clinical Professor of Family Medicine
UC Riverside School of Medicine
Director, Unger Concierge Primary Care Medical Group
Rancho Cucamonga, CA

Planning Committee

Gregg Sherman, MD
Chief Medical Officer/Course Director
National Association for Continuing Education
Plantation, FL

Deborah Paschal, CRNP
Course Director
Clinical Nurse Practitioner
Philadelphia, PA

Daniela Hiedra
Activity Director
National Association for Continuing Education

Plantation, FL

Sandy Bihlmeyer, M.Ed.
National Association for Continuing Education

Plantation, FL

Michelle Frisch, MPH, CHCP
National Association for Continuing Education

Plantation, FL

Harvey C. Parker, Ph.D., CHCP
National Association for Continuing Education

Plantation, FL

Cassandra A. McCullough, MBA

Chief Executive Officer

Association of Black Cardiologists

New York, NY

Joshua F. Kilbridge
President and Creative Director
Kilbridge Associates
San Francisco, CA

Sponsored and Certified By
National Association for Continuing Education & Association of Black Cardiologists Inc. & Albert Einstein College of Medicine
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 7.0 contact hours of continuing education, which includes 4.25 pharmacology hours.

Heart Failure: Optimizing Medical Therapy and Patient Communication provided by The Association of Black Cardiologist, Inc.
The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Optimizing COPD Management in Primary Care provided by Albert Einstein College of Medicine.
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Albert Einstein College of Medicine designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities provided by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosure will be provided in the activity materials.
Commercial Support
This educational activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., an educational grant from Sanofi US, an educational grant from Novartis Pharmaceuticals Corporation and an educational grant from GlaxoSmithKline.